Massachusetts gov trying to ban Zohydro; NICE slammed for limits to cancer drugs;

@FiercePharma: Top-read FP story yesterday: Merck, GlaxoSmithKline halt copay help for Obamacare patients. Story | Follow @FiercePharma

@TracyStaton: RT: Just out: today's full issue of FiercePharmaMarketing. More | Follow @TracyStaton

@EricPFierce: FDA's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. Article | Follow @EricPFierce

@CarlyHFierce: Check out FierceBiotech's new EuroBiotech report, which will run every Friday from here on out. Report | Follow @CarlyHFierce

> Massachusetts Governor Deval Patrick will try to ban sales of Zohydro there by declaring a health emergency around potential abuse of the high-powered painkiller. Story

> The FDA acknowledged meeting with the trial lawyers group, the American Association for Justice, when it was developing rules on labeling requirements for generic drugs. Story

> Congress will hold a trade hearing on U.S. efforts to oversee the safety of drug products coming out of China. Announcement

> A proposal by the U.K. drug price gatekeeper NICE to limit end-of-life use of some cancer drugs is coming under more criticism. Story

> An FTC official told a conference that the agency wants a $1 billion settlement from drug makers it has sued over pay-for-delay issues. Story

Medical Device News

@FierceMedDev: An analyst thinks Smith & Nephew should split into three pieces, and investors loved the idea. Story | Follow @FierceMedDev

@MarkHFierce: Check out FierceBiotech's debut EuroBiotech report. Report | Follow @MarkHFierce

@MichaelGFierce: Small, drug-releasing battery could dissolve completely over time. Article via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: GN Store Nord's U.S. customer base gets a boost thanks to its bluetooth-like hearing aid. Article | Follow @EmilyWFierce

> In Ohio, Steris slashes jobs and plans to close a plant. More

> Exact Sciences wins unanimous FDA committee approval for its colon cancer Dx. News

> NeuroSigma brings on two Amgen execs to bolster its finance team. Item

Biotech News

@FierceBiotech: Our 1st EuroBiotech Report: Merck KGaA R&D chief exits, Sobi drug flops in PhIII, Adaptimmune gets full-time CEO. Report | Follow @FierceBiotech

@JohnCFierce: Novartis is using Twitter to support its R&D team at adcomms? Social media won't substitute for another serelaxin trial. More | Follow @JohnCFierce

@DamianFierce: Syndax swings for a $69M IPO with 'breakthrough' drug in tow. News | Follow @DamianFierce

@EmilyMFierce: Report: U.S. can do more to support global health R&D. Article via FierceBiotech Research | Follow @EmilyMFierce

> Ebola still a tough target due to Big Pharma disinterest and few outbreaks. More

> MannKind faces stiff skepticism in its third go at FDA approval. Story

> AstraZeneca looks to China for kidney disease R&D. Item

And Finally... Former presidential candidate Newt Gingrich is calling for the FDA to be replaced, citing the recent controversy over whether biotech Chimerix could provide a dying child with an unapproved drug. Blog Post

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.